Emergent Biosolutions (NYSE:EBS) Coverage Initiated at JPMorgan Chase & Co.

Stock analysts at JPMorgan Chase & Co. initiated coverage on shares of Emergent Biosolutions (NYSE:EBS) in a research report issued to clients and investors on Friday. The brokerage set an “underweight” rating on the biopharmaceutical company’s stock.

A number of other analysts have also commented on the stock. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. HC Wainwright lowered their price objective on shares of Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Emergent Biosolutions in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Stock Performance

Shares of NYSE:EBS traded up $0.12 during midday trading on Friday, reaching $4.94. 138,060 shares of the company’s stock traded hands, compared to its average volume of 924,141. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06. The company has a market cap of $253.27 million, a price-to-earnings ratio of -1.39 and a beta of 2.35. The stock has a 50 day moving average of $7.17 and a 200 day moving average of $8.30.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The company had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. As a group, equities research analysts anticipate that Emergent Biosolutions will post -4.63 EPS for the current fiscal year.

Insider Activity

In related news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the sale, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new stake in shares of Emergent Biosolutions during the 2nd quarter valued at $31,000. Public Employees Retirement System of Ohio bought a new position in Emergent Biosolutions in the 2nd quarter worth $36,000. Torren Management LLC purchased a new position in Emergent Biosolutions during the fourth quarter valued at $37,000. CANADA LIFE ASSURANCE Co purchased a new position in Emergent Biosolutions during the fourth quarter valued at $45,000. Finally, Raymond James Financial Inc. bought a new stake in Emergent Biosolutions during the second quarter valued at about $53,000. 78.40% of the stock is currently owned by institutional investors.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.